Activity of Minocycline and Other Tetracyclines Against Tetracycline-Sensitive and -Resistant Staphylococci
N. A. Kuck, G.S. Redin, Martin Forbes
Abstract
N. A. Kuck, G.S. Redin, Martin Forbes
Abstract
Minocycline was more active than doxycycline, demethylchlortetracycline, methacycline, and tetracycline in vitro against 101 clinical staphylococcal isolates. It was the only analog active against all 48 tetracycline resistant strains at concentrations of 4 μg/ml or less. In mice, minocycline was the most potent analog against a tetracycline-sensitive staphylococcal infection and the only drug effective against a tetracycline-resistant staphylococcal infection. The results show that minocycline has a potential clinical advantage over tetracycline.
OpenAlex reports 22 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Minocycline was more active than doxycycline, demethylchlortetracycline, methacycline, and tetracycline in vitro against 101 clinical staphylococcal isolates. It was the only analog active against all 48 tetracycline resistant strains at concentrations of 4 μg/ml or less. In mice, minocycline was the most potent analog against a tetracycline-sensitive staphylococcal infection and the only drug effective against a tetracycline-resistant staphylococcal infection. The results show that minocycline has a potential clinical advantage over tetracycline.
Key concepts: Minocycline, Tetracycline, Doxycycline, Microbiology, Antibiotics, Staphylococcus, Oxytetracycline, Staphylococcus aureus